Stock Pick

Neuren Pharmaceuticals shares paused ahead of company announcement

Written by

openjargon

in

a woman wearing a dark business suit holds her hand up in a stop gesture while sitting at a desk. She has a sombre look on her face.

Neuren Pharmaceuticals Ltd (ASX: NEU) share price trading has been temporarily paused, pending a further announcement from the company, according to today’s ASX market release.

What did Neuren Pharmaceuticals report?

  • Trading in Neuren Pharmaceuticals shares has been paused by the ASX from 26 February 2026.
  • The company is yet to issue a further announcement explaining the reason for the pause.
  • No financial or operational results were reported in this particular market release.
  • Investors are awaiting more information from Neuren Pharmaceuticals management or the ASX.

What else do investors need to know?

A trading pause generally means the company is preparing a significant update or announcement. Until this announcement is made, shares will not trade on the ASX.

This could relate to a range of matters including financial results, a capital raise, or a market-sensitive development affecting the Neuren Pharmaceuticals share price.

What’s next for Neuren Pharmaceuticals?

Investors should keep a close eye on the ASX platform for Neuren’s next update. The pause will likely be lifted once the expected announcement is released.

We’ll bring you the latest as soon as more details become available.

Neuren Pharmaceuticals share price snapshot

Over the past 12 months, Neuren Pharmaceuticals shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 11% over the same period.

View Original Announcement

The post Neuren Pharmaceuticals shares paused ahead of company announcement appeared first on The Motley Fool Australia.

Should you invest $1,000 in Neuren Pharmaceuticals Limited right now?

Before you buy Neuren Pharmaceuticals Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuren Pharmaceuticals Limited wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 20 Feb 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

More posts